| INTRODUCTION
Chemotherapy drugs are commonly compounded in veterinary medicine to ensure smaller pets are safely dosed, to provide drugs in formulations that clients are able to administer to their pet, or when Food and Drug Administration (FDA)-approved formulations are unavailable. However, there is growing concern as to whether compounded medications are similar in efficacy to and of similar quality as FDA-approved products. Previous studies have evaluated omeprazole for horses and itraconazole, trilostane and ciclosporin in dogs and found that these compounded products were not equivalent in potency and resulted in treatment failures more frequently than the FDA-approved versions of the drugs. [1] [2] [3] [4] Recently, our group demonstrated neutropenia that occurred with greater frequency and severity in dogs treated with FDA-approved formulations of lomustine as compared with dogs administered a compounded product. 5 In addition, potency of the compounded formulations for 5 different compounding pharmacies ranged from 50% to 115% of the labelled concentration with only 1 of the samples within 10% of labelled concentration, which is the requirement for FDAapproved formulations. Evaluation of potential differences between compounded and FDA-approved formulations of lomustine was initiated as there was a clinical suspicion that neutropenia, and possibly tumour response, was occurring less frequently when dogs were treated with compounded lomustine. Potential differences in potency between compounded and FDA-approved product may not be as readily detected clinically with chemotherapy agents that are generally welltolerated by most dogs and cats, such as chlorambucil, melphalan and metronomic (low-dose) cyclophosphamide. In addition, these drugs are frequently used to treat more slowly progressing cancers and tend to be administered for a number of weeks before response to treatment can be assessed. [6] [7] [8] [9] Side effects associated with chlorambucil, Abbreviations: ACN, acetonitrile; BUD, beyond use date; FDA, Food and Drug Administration; m/z, mass to charge ratio; RT, room temperature; TFC, turbulent flow chromatography system; UV, ultraviolet melphalan and metronomic cyclophosphamide occur less frequently and predictably than for other cytotoxic drugs and when side effects do occur, it may take weeks to months before they are detected. 8, 10, 11 This raises concerns that recognition of sub-therapeutic dosing could be delayed, resulting in administration of an ineffective cancer therapeutic for an extended period of time.
Despite wide use clinically, the potency and stability of compounded oral chemotherapy drugs have not been extensively evaluated to date. A recent publication demonstrated that 40% of samples of compounded cyclophosphamide had an actual potency that was greater than AE10% the labelled concentration of drug; 1 sample had a potency of <10% of labelled concentration 60 days after receipt, indicating that stability of compounded chemotherapy drugs may be an issue as well. 12 This study raises further concern that compounded chemotherapy agents may not be as stable or as potent as their FDAapproved product. Concerns regarding stability may be particularly critical for drugs that are to be administered over weeks or months.
The objective of this study was to assess variability in greater detail in potency and stability of compounded formulations of 3 commonly compounded oral chemotherapy drugs, chlorambucil, melphalan and cyclophosphamide.
| MATERIALS AND METHODS
Compounded oral chemotherapy drugs were purchased from 6 com- Quanbrowser software was used to generate calibration curves and quantitate all analytes by linear regression analysis. A weighting factor of 1/X was used for all calibration curves. The responses were linear and gave correlation coefficients (R 2 ) of 0.99 or better.
Samples with a potency of AE10% of labelled strength were considered to have acceptable potency. Mean potency for the individual samples tested for each chemotherapy drug are provided in Table 1 . Potency of compounded chlorambucil ranged from 71% to 104% on day 0 and 73% to 103% on 6 weeks after initial testing ( Figure 1A ). One out of 4 samples was below 90% potency on both day 0 and day 42. Another compounded chlorambucil sample was of adequate potency on day 0 but potency of this product decreased to 74% of the labelled concentration at day 42. The other 2 samples remained within AE10% of labelled concentration at both day 0 and day 42. Samples 2A and 4A were stored at RT; samples 3A and 5A were stored at 4 C ( Figure 1A ).
| RESULTS

Compounded
Potency of compounded melphalan ranged from 65% to 109% on day 0 and 58% to 109% 6 weeks after initial testing ( Figure 1B ).
One out of 4 samples was below 90% potency on both day 0 and day 42. Another compounded melphalan sample was of adequate potency (96%) on day 0 but potency decreased to 89% of the labelled concentration at day 42. The other 2 samples remained within AE10% of labelled concentration at both day 0 and day 42.
Samples 2B and 3B were stored at RT; samples 4B and 5B were stored at 4 C ( Figure 1B ). All compounded melphalan samples decreased in potency over the 6-week study period (range: −6.25%
to −12.8%).
Potency of compounded cyclophosphamide ranged from 92% to 107% on day 0 and 90% to 99% 6 weeks after initial testing ( Figure 1C ). All compounded cyclophosphamide samples remained within AE10% of labelled concentration at both day 0 and day 42; all were stored at RT for the duration of the study. Four out of the 5 compounded cyclophosphamide samples decreased in potency over the 6-week study period (range: −1.0% to −12.6%).
| DISCUSSION
Compounding of pharmaceuticals is essential in veterinary medicine
to ensure patients can be treated safely and accurately. This is particularly critical for drugs that have a narrow therapeutic window with the potential for serious significant side effects with over-dosing or therapeutic failure if under-dosing occurs. Our previous research indicated that potency of compounded lomustine was highly variable and as a result, dogs that were treated with compounded lomustine did not develop neutropenia as frequently or to the degree of severity as dogs treated with FDA-approved formulations of lomustine. The oral chemotherapy drugs evaluated for potency in this study do not have as predictable side effect profile as lomustine and when side effects occur, it often occurs after prolonged administration of the drug. In addition, compounded lomustine is generally administered at the time it is prescribed, whereas many other drugs will be sent home to be administered continuously on a daily or every other day basis, making stability of these compounded products as important as potency.
Chlorambucil, melphalan and metronomic (or low-dose) cyclophosphamide are frequently used to treat cancers that respond to or progress after treatment more gradually, such as small cell gastrointestinal lymphoma in cats, multiple myeloma and incompletely resected soft tissue sarcomas in dogs. 7, 8, 10 As the drugs are generally well-tolerated by dogs and cats and it may take weeks to months before toxicities and/or responses to treatment to develop, it is critical that veterinarians have assurance that the products they are prescribing are as potent and stable as FDA-approved chemotherapy agents to ensure patients that "fail" treatment do so because their cancer did not respond to the drug, rather than receiving subtherapeutic treatment for prolonged intervals.
As with our previous investigation into the potency of compounded lomustine, we have again elected not to identify the compounding pharmacies from which compounded chlorambucil, melphalan and cyclophosphamide were obtained for analysis. Results of the previous studies evaluating potency of lomustine and cyclophosphamide support that potency of the same drug obtained from period. 12 All samples of compounded cyclophosphamide obtained in this study were within 90%-110% of labelled concentration both at baseline and at the 6-week time point; however, 3 samples had decreases in potency of 6.2%, 7.5% and 12.6% over the 6-week period.
This raises the concern that perhaps some of these samples would no longer be of acceptable potency if re-tested at 60 days.
Melphalan and chlorambucil showed a bit more variability in potency than compounded cyclophosphamide in this study. Storage conditions for FDA-approved melphalan and chlorambucil is 4 C, but only 2 of 5 of the compounding pharmacies recommended refrigerated storage for compounded melphalan and chlorambucil.
This may have impacted potency for these 2 drugs to some degree, particularly for chlorambucil sample A4 (Figure 1 ), which was stored at RT and had the greatest decrease in potency. Storage conditions during the 6-week stability period do not fully explain the variability in potency at baseline and at 6 weeks as some samples with unacceptable potency at baseline were stored at the proper storage conditions during the course of the study. To better assess the impact of storage temperature on product stability, future studies could be designed to divide compounded samples and controls upon receipt with a portion held at RT and the rest at 4 C for the duration of the stability period. This would allow for direct comparisons of differences in potency that may occur for products held at 4 C vs RT. Thorough assessment of why such variability may occur and the repeatability of these findings over a period of time was beyond the scope of this work as many of these variables likely occur at the compounding pharmacies prior to dispensing of the compounded product.
Beyond the issue of potency and stability of compounded drugs, prescribers of these medications need to consider the issue of bioequivalence of compounded products as compared with FDAapproved products. The process of and products used for compounding could alter the pharmacokinetic parameters when these oral medications are administered to veterinary patients; however, bioequivalence testing of compounded products has not routinely been performed to date in veterinary medicine. However, compounded omeprazole administered to horses and compounded intraconazole administered to healthy research dogs have previously demonstrated that substantial pharmacokinetic alterations may occur when compared with the FDA-approved products. 3, 4 Further work is need to assess bioequivalence of compounded products in clinical veterinary patients to better understand the potential therapeutic impact beyond potency testing alone.
In conclusion, these findings, in combination with previous investigations into the variability of potency of compounded drugs, should stimulate veterinarians to carefully weigh the benefits and potential risks of prescribing compounded formulations of chemotherapy drugs.
The observed decreases in potency of some compounds over time may also discourage prescribing or ordering large quantities of compounded drugs that are to be continuously administered, particularly in light of the decreasing potency of some of these compounded products despite testing well within the BUD provided by the compounding pharmacy.
Lastly, if greater oversight or voluntary assurance testing of compounds by individual compounding pharmacies is instituted in the future, both potency and stability should be considered. 
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